drugset / Trial / NCT01946620

A Study to Show That Flutiform is Well Tolerated and Effective in the Treatment of COPD

NCT01946620

Phase 3 Completed 1767 enrolled Mundipharma Research Limited
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Efficacy of Fluticasone/Formoterol in COPD Treatment. The Effect study.

Timeline

Start
2013-10
Primary completion
2016-04
Completion
2016-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluticasone propionate Other / unclassified 125 ug Inhaled
Subject Fluticasone propionate Other / unclassified 250 ug Inhaled
Comparator Formoterol Other / unclassified 5 ug Inhaled
Comparator Formoterol Other / unclassified 10 ug Inhaled
Comparator Formoterol Other / unclassified 12 ug Inhaled